Thursday, September 10, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 2, 2026

Medtronic Diabetes expands access to full-stack insulin delivery solutions with Medicare access and new FDA clearances

View original at finance.yahoo.com
Medtronic Diabetes expands access to full-stack insulin delivery solutions with Medicare access and new FDA clearances GALWAY, Ireland, Feb…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • By broadening sensor and insulin options for the MiniMed 780G system, more people will benefit from automated insulin delivery that supports easier mealtimes, greater flexibility, and more confident diabetes management

    80% confidence
  • Instinct sensor offers up to 15 days of wear and is the world's smallest and thinnest integrated CGM

    80% confidence
  • More people living with type 2 diabetes will get access to life-changing technology improving their day-to-day experience in managing their diabetes

    80% confidence
  • MiniMed 780G system automatically adjusts insulin delivery every five minutes, responding to glucose changes, supporting more stable glucose control with fewer highs and lows and less daily decision-making

    80% confidence
  • Anyone who requires insulin therapy to manage their diabetes, whether type 1 or type 2, can benefit from automated insulin delivery

    80% confidence
  • Bringing together the Instinct sensor with the well-established algorithm of the MiniMed 780G system makes for an extremely effective combination

    80% confidence
  • Medtronic technologies and therapies treat 70 health conditions and transform the lives of two people every second, every hour, every day

    80% confidence
  • Ultra rapid-acting insulin's faster onset may help reduce the impact of late or missed meal doses, allowing the insulin to catch up more effectively

    80% confidence
  • These milestones reflect unwavering commitment to expanding access and giving individuals living with diabetes more choice in how they manage their condition

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Capital Boom Meets Valuation Jitters: Funding Surges While Bellwether Stocks Wobble
A dense wave of AI-sector funding (Socure, Stability AI, Emerald AI, Generalist AI, Gatik, Regent Craft and others closing rounds on the same day) and strong enterprise-automation earnings (UiPath raising full-year guidance) point to continued heavy capital deployment into AI infrastructure, fintech-adjacent AI, and agentic automation. Yet Palantir's stock fell even after winning the Army's high-profile TITAN contract, and commentary (e.g., the Alphabet bull case citing AI capex and regulatory risk) signals growing investor unease about whether current AI valuations and spending levels are sustainable.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
JPMorgan Chase & Co.
Both facts represent the same entity (JPMorgan Chase & Co.), same attribute (EPS), and same observation date (2025-12-31), which aligns with FY 2025 year-end reporting. Fact A explicitly states FY 2025 with EPS of 20.02 USD/share. Fact B has an unspecified fiscal period (N/A) but reports 4.63 USD, a significantly different value (4.3x lower). Given identical observation dates and the same metric, both facts appear intended to represent FY 2025 annual EPS. The conflicting values (20.02 vs 4.63) constitute a direct contradiction. The N/A period in Fact B suggests incomplete or corrupted metadata rather than legitimate time-period variation.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,981
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,981 facts checked against source5,278 source documents archived
Query this data → isubstrate.com
Medtronic Diabetes expands access to full-stack insulin delivery solutions with Medicare access and new FDA clearances — Source | Via News | Via News